News

Archer-Daniels-Midland: We Are Again Right On Target, Slowdown Is Part Of Normalization

4 Mins read

Investment Thesis

Review

We initially covered Archer-Daniel-Midland at $89.41 in February this year with a “Sell” rating, and it subsequently realized an 18% decline to $72.62 by June. At that point, we changed our rating to “Hold”, expecting the price movement

Read the full article here

Related posts
News

Cidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b Readout (CDTX)

1 Mins read
This article was written by Follow Background: Physician involved in clinical research. Investment style: Clinical-stage biotech stocks, long only, both long-term ideas and event-driven…
News

Galiano Gold Inc. (GAU) Q2 2025 Earnings Call Transcript

1 Mins read
Galiano Gold Inc. (NYSE:GAU) Q2 2025 Earnings Conference Call August 14, 2025 10:30 AM ET Company Participants Matt Badylak – President, CEO…
News

Similarweb Ltd. 2025 Q2 - Results - Earnings Call Presentation (NYSE:SMWB)

1 Mins read
Q2: 2025-08-12 Earnings Summary EPS of $0.01 beats by $0.02  | Revenue of $70.97M (17.03% Y/Y) beats by $2.15M This article was written…
Get The Latest News

Subscribe to get the top fintech and
finance news and updates.

Leave a Reply

Your email address will not be published. Required fields are marked *